216 related articles for article (PubMed ID: 25436495)
1. Retinoblastoma: evidence for postenucleation adjuvant chemotherapy.
Kim JW
Int Ophthalmol Clin; 2015; 55(1):77-96. PubMed ID: 25436495
[No Abstract] [Full Text] [Related]
2. Retinoblastoma: approaching international standards for recommending chemotherapy (Commentary on Chantada et al., page 692).
Meadows AT
Pediatr Blood Cancer; 2008 Mar; 50(3):521-2. PubMed ID: 18186114
[No Abstract] [Full Text] [Related]
3. [Retinoblastoma metastatic to the parotid gland: A case report].
Zrafi WS; Kanoun Belajouza S; Mestiri S; Mokni M; Bouaouina N
J Fr Ophtalmol; 2018 Apr; 41(4):e141-e143. PubMed ID: 29655578
[No Abstract] [Full Text] [Related]
4. Retinoma underlying retinoblastoma revealed after tumor response to 1 cycle of chemotherapy.
Dimaras H; Khetan V; Halliday W; Héon E; Chan HS; Gallie BL
Arch Ophthalmol; 2009 Aug; 127(8):1066-8. PubMed ID: 19667353
[No Abstract] [Full Text] [Related]
5. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group.
Chantada GL; Doz F; Orjuela M; Qaddoumi I; Sitorus RS; Kepak T; Furmanchuk A; Castellanos M; Sharma T; Chevez-Barrios P; Rodriguez-Galindo C;
Pediatr Blood Cancer; 2008 Mar; 50(3):692-4. PubMed ID: 18059037
[TBL] [Abstract][Full Text] [Related]
6. [Current therapeutic management in retinoblastoma with invasion of the optic nerve--a case report].
Gavriş M; Neamţu S; Gavriş S; Ghiţuică A
Oftalmologia; 1999; 46(1):69-71. PubMed ID: 10641091
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma.
Chantada GL; Dunkel IJ; Antoneli CB; de Dávila MT; Arias V; Beaverson K; Fandiño AC; Chojniak M; Abramson DH
Pediatr Blood Cancer; 2007 Sep; 49(3):256-60. PubMed ID: 17029248
[TBL] [Abstract][Full Text] [Related]
8. A perspective on chemoreduction and focal therapy for retinoblastoma.
Balasubramanya R; Pushker N; Bajaj MS; Ghose S; Rani A
Am J Ophthalmol; 2002 Oct; 134(4):633; author reply 633-4. PubMed ID: 12383837
[No Abstract] [Full Text] [Related]
9. Superselective intra-arterial chemotherapy for advanced retinoblastoma complicated by metastatic disease.
Mathew AA; Sachdev N; Staffieri SE; McKenzie JD; Elder JE
J AAPOS; 2015 Feb; 19(1):72-4. PubMed ID: 25727592
[TBL] [Abstract][Full Text] [Related]
10. High Risk Retinoblastoma: Prevalence and Success of Treatment in Developing Countries.
ElZomor H; Taha H; Aleieldin A; Nour R; Zaghloul MS; Fawzi M; Kamel A; Alfaar AS
Ophthalmic Genet; 2015; 36(3):287-9. PubMed ID: 25945688
[No Abstract] [Full Text] [Related]
11. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.
Vajzovic LM; Murray TG; Aziz-Sultan MA; Schefler AC; Fernandes CE; Wolfe SC; Hess DJ; Dubovy SR
Arch Ophthalmol; 2010 Dec; 128(12):1619-23. PubMed ID: 21149791
[No Abstract] [Full Text] [Related]
12. Treatment of overt extraocular retinoblastoma.
Chantada G; Fandiño A; Casak S; Manzitti J; Raslawski E; Schvartzman E
Med Pediatr Oncol; 2003 Mar; 40(3):158-61. PubMed ID: 12518344
[TBL] [Abstract][Full Text] [Related]
13. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis.
Zhao J; Dimaras H; Massey C; Xu X; Huang D; Li B; Chan HS; Gallie BL
J Clin Oncol; 2011 Mar; 29(7):845-51. PubMed ID: 21282531
[TBL] [Abstract][Full Text] [Related]
14. Chemoreduction in the management of retinoblastoma.
Shields JA; Shields CL; Meadows AT
Am J Ophthalmol; 2005 Sep; 140(3):505-6. PubMed ID: 16139001
[No Abstract] [Full Text] [Related]
15. Histopathologic changes in retinoblastoma after chemoreduction.
Dithmar S; Aabert TM; Grossniklaus HE
Retina; 2000; 20(1):33-6. PubMed ID: 10696744
[TBL] [Abstract][Full Text] [Related]
16. A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali.
Boubacar T; Fatou S; Fousseyni T; Mariam S; Fatoumata DT; Toumani S; Abdoul-Aziz D; Marouf KM
Br J Ophthalmol; 2010 Apr; 94(4):467-9. PubMed ID: 19822911
[TBL] [Abstract][Full Text] [Related]
17. Advanced unilateral retinoblastoma: a case of sparing enucleation treatment failure.
Valente P; De Ioris MA; Romanzo A; Cozza R; Natali G; Buzzonetti L
Can J Ophthalmol; 2016 Apr; 51(2):e40-3. PubMed ID: 27085272
[No Abstract] [Full Text] [Related]
18. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.
Kaliki S; Shields CL; Shah SU; Eagle RC; Shields JA; Leahey A
Arch Ophthalmol; 2011 Nov; 129(11):1422-7. PubMed ID: 22084213
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy?
Chantada GL; Dunkel IJ; de Dávila MT; Abramson DH
Br J Ophthalmol; 2004 Aug; 88(8):1069-73. PubMed ID: 15258027
[TBL] [Abstract][Full Text] [Related]
20. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation.
Aerts I; Sastre-Garau X; Savignoni A; Lumbroso-Le Rouic L; Thebaud-Leculée E; Frappaz D; Coze C; Thomas C; Gauthier-Villars M; Lévy-Gabriel C; Brisse HJ; Desjardins L; Doz F
J Clin Oncol; 2013 Apr; 31(11):1458-63. PubMed ID: 23460706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
